Moreover, Cd38-/- mice display milder colitis, suggesting that the upregulation of this molecule is pathogenic in IBD and that therapeutic modalities targeting CD38 in cancer and aging might also be relevant for this disease [30–32]. This evidence concerns the gene CD38 and inflammatory bowel disease.